246 related articles for article (PubMed ID: 31155415)
1. Safety and immunogenicity of a replication-deficient H5N1 influenza virus vaccine lacking NS1.
Nicolodi C; Groiss F; Kiselev O; Wolschek M; Seipelt J; Muster T
Vaccine; 2019 Jun; 37(28):3722-3729. PubMed ID: 31155415
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1.
Mössler C; Groiss F; Wolzt M; Wolschek M; Seipelt J; Muster T
Vaccine; 2013 Dec; 31(52):6194-200. PubMed ID: 24183981
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.
Pitisuttithum P; Boonnak K; Chamnanchanunt S; Puthavathana P; Luvira V; Lerdsamran H; Kaewkungwal J; Lawpoolsri S; Thanachartwet V; Silachamroon U; Masamae W; Schuetz A; Wirachwong P; Thirapakpoomanunt S; Rudenko L; Sparrow E; Friede M; Kieny MP
Lancet Infect Dis; 2017 Aug; 17(8):833-842. PubMed ID: 28533093
[TBL] [Abstract][Full Text] [Related]
4. Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines.
Wang P; Zheng M; Lau SY; Chen P; Mok BW; Liu S; Liu H; Huang X; Cremin CJ; Song W; Chen Y; Wong YC; Huang H; To KK; Chen Z; Xia N; Yuen KY; Chen H
mBio; 2019 Sep; 10(5):. PubMed ID: 31530680
[TBL] [Abstract][Full Text] [Related]
5. A novel type of influenza vaccine: safety and immunogenicity of replication-deficient influenza virus created by deletion of the interferon antagonist NS1.
Wacheck V; Egorov A; Groiss F; Pfeiffer A; Fuereder T; Hoeflmayer D; Kundi M; Popow-Kraupp T; Redlberger-Fritz M; Mueller CA; Cinatl J; Michaelis M; Geiler J; Bergmann M; Romanova J; Roethl E; Morokutti A; Wolschek M; Ferko B; Seipelt J; Dick-Gudenus R; Muster T
J Infect Dis; 2010 Feb; 201(3):354-62. PubMed ID: 20039806
[TBL] [Abstract][Full Text] [Related]
6. Development of a dual-protective live attenuated vaccine against H5N1 and H9N2 avian influenza viruses by modifying the NS1 gene.
Choi EH; Song MS; Park SJ; Pascua PN; Baek YH; Kwon HI; Kim EH; Kim S; Jang HK; Poo H; Kim CJ; Choi YK
Arch Virol; 2015 Jul; 160(7):1729-40. PubMed ID: 25959557
[TBL] [Abstract][Full Text] [Related]
7. Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza.
Steel J; Lowen AC; Pena L; Angel M; Solórzano A; Albrecht R; Perez DR; García-Sastre A; Palese P
J Virol; 2009 Feb; 83(4):1742-53. PubMed ID: 19073731
[TBL] [Abstract][Full Text] [Related]
8. [Preclinical studies of live intranasal H5N1 influenza vaccine with the deleted HS1 gene].
Romanovskaia-Roman'ko EA; Ferko B; Vyshemirskiĭ OI; Romanova IuR; Krenn B; Muster T; Grudinin MP; Lapin BA; Egorov AIu; Kiselev OI
Vopr Virusol; 2011; 56(6):19-22. PubMed ID: 22359944
[TBL] [Abstract][Full Text] [Related]
9. Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine.
Rudenko L; Naykhin A; Donina S; Korenkov D; Petukhova G; Isakova-Sivak I; Losev I; Stukova M; Erofeeva M; Nikiforova A; Power M; Flores J
Hum Vaccin Immunother; 2015; 11(12):2839-48. PubMed ID: 26697973
[TBL] [Abstract][Full Text] [Related]
10. Single HA2 mutation increases the infectivity and immunogenicity of a live attenuated H5N1 intranasal influenza vaccine candidate lacking NS1.
Krenn BM; Egorov A; Romanovskaya-Romanko E; Wolschek M; Nakowitsch S; Ruthsatz T; Kiefmann B; Morokutti A; Humer J; Geiler J; Cinatl J; Michaelis M; Wressnigg N; Sturlan S; Ferko B; Batishchev OV; Indenbom AV; Zhu R; Kastner M; Hinterdorfer P; Kiselev O; Muster T; Romanova J
PLoS One; 2011 Apr; 6(4):e18577. PubMed ID: 21490925
[TBL] [Abstract][Full Text] [Related]
11. A live attenuated H5N2 prime- inactivated H5N1 boost vaccination induces influenza virus hemagglutinin stalk specific antibody responses.
Kongchanagul A; Samnuan K; Wirachwong P; Surichan S; Puthavathana P; Pitisuttithum P; Boonnak K
Vaccine; 2020 Jan; 38(4):852-858. PubMed ID: 31708176
[TBL] [Abstract][Full Text] [Related]
12. Cross-clade protective immune responses of NS1-truncated live attenuated H5N1 avian influenza vaccines.
Shi S; Chen S; Han W; Wu B; Zhang X; Tang Y; Wang X; Zhu Y; Peng D; Liu X
Vaccine; 2016 Jan; 34(3):350-7. PubMed ID: 26638027
[TBL] [Abstract][Full Text] [Related]
13. Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial.
Howard LM; Hoek KL; Goll JB; Samir P; Galassie A; Allos TM; Niu X; Gordy LE; Creech CB; Prasad N; Jensen TL; Hill H; Levy SE; Joyce S; Link AJ; Edwards KM
PLoS One; 2017; 12(1):e0167488. PubMed ID: 28099485
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.
van der Velden MV; Geisberger A; Dvorak T; Portsmouth D; Fritz R; Crowe BA; Herr W; Distler E; Wagner EM; Zeitlinger M; Sauermann R; Stephan C; Ehrlich HJ; Barrett PN; Aichinger G
Clin Vaccine Immunol; 2014 Jun; 21(6):867-76. PubMed ID: 24739978
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.
Kreijtz JH; Goeijenbier M; Moesker FM; van den Dries L; Goeijenbier S; De Gruyter HL; Lehmann MH; Mutsert Gd; van de Vijver DA; Volz A; Fouchier RA; van Gorp EC; Rimmelzwaan GF; Sutter G; Osterhaus AD
Lancet Infect Dis; 2014 Dec; 14(12):1196-207. PubMed ID: 25455987
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR;
JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults.
Karron RA; Talaat K; Luke C; Callahan K; Thumar B; Dilorenzo S; McAuliffe J; Schappell E; Suguitan A; Mills K; Chen G; Lamirande E; Coelingh K; Jin H; Murphy BR; Kemble G; Subbarao K
Vaccine; 2009 Aug; 27(36):4953-60. PubMed ID: 19540952
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
[TBL] [Abstract][Full Text] [Related]
20. Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans.
Overton ET; Goepfert PA; Cunningham P; Carter WA; Horvath J; Young D; Strayer DR
Vaccine; 2014 Sep; 32(42):5490-5. PubMed ID: 25128802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
